(Total Views: 300)
Posted On: 07/06/2022 4:53:02 PM
Post# of 8452
"The chronic pain market is larger than that of diabetes, heart disease and cancer, with 20% of adults globally suffering from chronic pain.
ActiPatch addresses the unmet needs of 1.5 billion people living with chronic pain worldwide.
The company’s medical devices regulate the body’s nerve activity to reduce the perception of pain, thereby reducing drug use. RecoveryRx would be an ideal option for reducing postoperative pain and exposure to the long-term effects of opioid/NSAID therapy."
Source:
March 13, 2022, 9:45 AM
BioElectronics Corp. (OTCPINK:BIEL) Rapidly Gaining New Orders as Biotech Begins New Studies and Its RecoveryRx, ActiPatch Gain Traction – Maryland News
https://darik.news/maryland/bioelectronics-co...31396.html
ActiPatch addresses the unmet needs of 1.5 billion people living with chronic pain worldwide.
The company’s medical devices regulate the body’s nerve activity to reduce the perception of pain, thereby reducing drug use. RecoveryRx would be an ideal option for reducing postoperative pain and exposure to the long-term effects of opioid/NSAID therapy."
Source:
March 13, 2022, 9:45 AM
BioElectronics Corp. (OTCPINK:BIEL) Rapidly Gaining New Orders as Biotech Begins New Studies and Its RecoveryRx, ActiPatch Gain Traction – Maryland News
https://darik.news/maryland/bioelectronics-co...31396.html
(2)
(0)
